Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Abstract Background Final data are presented for the ORAL Sequel long-term extension (LTE) study evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 years in patients with rheumatoid arthritis (RA). Methods Eligible patients had previously completed a pha...

Full description

Bibliographic Details
Main Authors: Jürgen Wollenhaupt, Eun-Bong Lee, Jeffrey R. Curtis, Joel Silverfield, Ketti Terry, Koshika Soma, Chris Mojcik, Ryan DeMasi, Sander Strengholt, Kenneth Kwok, Irina Lazariciu, Lisy Wang, Stanley Cohen
Format: Article
Language:English
Published: BMC 2019-04-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Tofacitinib
Long-term extension
Online Access:http://link.springer.com/article/10.1186/s13075-019-1866-2

Internet

http://link.springer.com/article/10.1186/s13075-019-1866-2

Similar Items